OREANDA-NEWS. January 24, 2007. OJSC Pharmstandard (LSE: PHST LI, RTS: PHST RU) announced an acquisition of 19,88% shares of "DIPAKA TRAIDING LIMITED", Cyprus, for US$10 million. Pharmstandard financed the transaction through the operational cash-on-hand.
 
"DIPAKA TRAIDING LIMITED" owns 100% shares of Russian pharmaceutical company Mirpharm and several patents and trademarks, including Mexiprim®. Mirpharm is Russian highly technological API producer and holds research base for drugs and APIs development.
 
According to contract with Mirpharm, Pharmstandard accomplishes exclusive distribution and promotion of Mexiprim®. In future, Pharmstandard plans to use Mirpharm R&D resources for development and production of drugs and APIs.